Notice to attend the Annual General Meeting
NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December…
Year-end report 2018-09-01 - 2019-08-31
Nextcell Pharma AB (“NXTCL”) today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) Operating income amounted to SEK 1 964 132 (655 413)….
NextCell invests in the Danish Cellaviva operations with a new Copenhagen office
NextCell Pharma AB (“NextCell”) today announces they are investing for growth in Cellaviva’s Danish operations with the opening of a new Copenhagen office. In October, Cellaviva’s new office was opened…
All patients in ProTrans-Repeat are now treated
NextCell Pharma AB (“NextCell”) announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This…
Last patient, last visit completed in the dose escalation part
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today…
Update on the ongoing clinical trials
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were…
NextCell Pharma files another patent application
NextCell Pharma AB (“NextCell”) today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company’s proprietary selection algorithm,…
Interim report 2018-09-01 - 2019-05-31
Third quarter report By “NextCell”, “NXTCL” or “Company” is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight” refers to the Spotlight Stock Market (previous AktieTorget). Amount in brackets refer…
A letter to NextCell’s Investors
NextCell Pharma AB (“NextCell”) has published a letter to the investors with summer greetings from CEO Mathias Svahn. The attached letter is in Swedish and can also be found on…
Final patient treated in the phase II part of the ProTrans-1 trial
NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have…
New collaboration and increased digital presence - Cellaviva is gearing for growth
NextCell Pharma AB (“NextCell”) today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB (“Bonzun”), who are providing the first global health…
NextCell has treated the first patient in the ProTrans-Repeat trial
NextCell Pharma AB (NextCell) announces that earlier today the first patient was treated as part of the ProTrans-Repeat trial, which is NextCell’s second clinical trial. ProTrans-Repeat is a Phase IIa…
